At Alaya.bio, we're developing a revolutionary targeting polymeric nanoparticle that enhances the transduction efficiency of quiescent cells such as T-cells, NK-cells, and stem cells. Our platform eliminates the need for activation factors or cytokines, resulting in reduced exhaustion of transduced cells while preserving their naive and memory phenotypes, leading to better clinical outcomes.
| Website | http://www.alaya.bio |
| Employees | 21 (19 on RocketReach) |
| Founded | 2022 |
| Address | 139 Main Street, Cambridge, Massachusetts, US |
| Phone | +1 212-463-9791 |
| Industry | Biotechnology Research |
| Keywords | Nanoparticle Drug Delivery, Advanced Drug Delivery, Targeted Therapies, Targeted Drug Delivery, Nanomedicine, Drug Delivery Platform, T Cell Therapy, Nk Cell Therapy, Polymer Chemistry, Pharmaceutical Research, Precision Medicine, Stem Cell Therapy, Therapeutic Development, Regenerative Medicine, Biotechnology, Immunotherapy |
| Competitors | Geno, Zymergen, Inc., Codexis, Inc., LanzaTech, Amyris, Arzeda, Chrysalix Venture Capital, Ecovative, Sustainable Bioproducts, Nanollose Ltd +20 more (view full list) |
Looking for a particular Alaya.bio employee's phone or email?
Alaya.bio Questions
Cécile Bauche is the Founder and CSO of Alaya.bio.
19 people are employed at Alaya.bio.
Alaya.bio is based in Cambridge, Massachusetts.
Top Alaya.bio Employees
-
21
-
33
-
1
-
Stefan Wildt
Executive Chair at Alaya.bio
Cambridge, MA, US25+ -
21
-
1
G2Crowd Trusted
300K+
Plugin Users
